Executive Series 26 Jun 18: Wattle Health Australia (WHA) CEO, Lazarus Karasavvidis, page-92

Just a quick analyse, it will be huge for WHA if they can get that SAMR registration. Last year's total revenue was about $1mil and the potential to reach about $140mil in 4yrs will be huge.

A2M have the advantage of the Daigou's free marketing while WHA seem to have established the distribution point even while waiting for the SAMR to be issued. A2M is a beast in their own right right now with a market cap of about 8bils but WHA have about 7 times lesser in term of total share volume in comparison to A2M. If WHA soon be able to get the SAMR then sky is the limit. It will de-risk alot and $3 is not out of the question if looking at A2M's performance at the time of CFDA issued. SAMR is critical and then after that it will be about marketing and promoting and signing up for more distribution points and then making sure they have enough supply. The Chinese market will be very important for WHA.

IMHO, A2M, BUBS, BAL and WHA are all great stocks to own.

Until then we will all just have to wait for that SAMR. GLTAL!